4,000 Shares in Sanofi (SNY) Acquired by FNY Partners Fund LP

FNY Partners Fund LP purchased a new position in shares of Sanofi (NYSE:SNY) during the fourth quarter, Holdings Channel reports. The fund purchased 4,000 shares of the company’s stock, valued at approximately $162,000.

Several other hedge funds also recently made changes to their positions in the stock. Telos Capital Management Inc. boosted its stake in shares of Sanofi by 5.8% in the second quarter. Telos Capital Management Inc. now owns 33,418 shares of the company’s stock worth $1,399,000 after buying an additional 1,831 shares during the period. Coconut Grove Bank boosted its stake in Sanofi by 175.5% in the second quarter. Coconut Grove Bank now owns 11,069 shares of the company’s stock worth $463,000 after buying an additional 7,051 shares during the last quarter. Oxbow Advisors LLC acquired a new stake in Sanofi during the second quarter worth about $3,507,000. ProVise Management Group LLC boosted its stake in Sanofi by 1.5% in the second quarter. ProVise Management Group LLC now owns 43,630 shares of the company’s stock worth $1,826,000 after buying an additional 625 shares during the last quarter. Finally, World Asset Management Inc boosted its stake in Sanofi by 8.1% in the second quarter. World Asset Management Inc now owns 119,205 shares of the company’s stock worth $4,989,000 after buying an additional 8,882 shares during the last quarter. 9.73% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Shares of Sanofi (NYSE:SNY) traded down 0.30% during trading on Friday, hitting $42.57. 1,159,991 shares of the stock traded hands. Sanofi has a 52 week low of $36.81 and a 52 week high of $44.50. The firm has a market cap of $109.23 billion, a P/E ratio of 21.65 and a beta of 0.98. The company has a 50-day moving average of $40.57 and a 200-day moving average of $39.74.

Sanofi (NYSE:SNY) last posted its quarterly earnings data on Wednesday, February 8th. The company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.01. The company had revenue of $8.88 billion for the quarter, compared to analyst estimates of $9.87 billion. Sanofi had a return on equity of 26.37% and a net margin of 13.66%. The firm’s quarterly revenue was down 4.3% on a year-over-year basis. On average, analysts forecast that Sanofi will post $3.05 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “4,000 Shares in Sanofi (SNY) Acquired by FNY Partners Fund LP” was first published by sleekmoney and is the sole property of of sleekmoney. If you are reading this article on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this article can be viewed at http://sleekmoney.com/4000-shares-in-sanofi-sny-acquired-by-fny-partners-fund-lp/1656860.html.

A number of analysts recently issued reports on the company. Natixis raised Sanofi from a “neutral” rating to a “buy” rating in a research note on Thursday. Leerink Swann reissued an “outperform” rating on shares of Sanofi in a research note on Tuesday, January 10th. Zacks Investment Research cut Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, February 7th. Goldman Sachs Group, Inc. (The) reissued a “hold” rating on shares of Sanofi in a research note on Sunday, January 8th. Finally, Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, November 29th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $65.67.

Sanofi Company Profile

Sanofi SA, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. It operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

5 Day Chart for NYSE:SNY

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/4000-shares-in-sanofi-sny-acquired-by-fny-partners-fund-lp/1656860.html

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *